ARGENX SE

ARGX Nasdaq CIK: 0001697862

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type other
SEC Category Large accelerated filer
State of Incorporation Netherlands
Country Belgium
Business Address INDUSTRIEPARK ZWIJNAARDE 7, ZWIJNAARDE, ,
Mailing Address INDUSTRIEPARK ZWIJNAARDE 7, ZWIJNAARDE, ,
Phone 32 (9) 310 34 00
Fiscal Year End 1231
EIN 000000000

Recent SEC Filings

Form Type Date Filed Document
6-K Foreign company current report March 20, 2026 View on SEC
6-K Foreign company current report March 19, 2026 View on SEC
20-F Foreign company annual report March 19, 2026 View on SEC
6-K Foreign company current report March 6, 2026 View on SEC
6-K Foreign company current report February 26, 2026 View on SEC
6-K Foreign company current report February 26, 2026 View on SEC
6-K Foreign company current report January 13, 2026 View on SEC
6-K Foreign company current report January 12, 2026 View on SEC
6-K Foreign company current report January 5, 2026 View on SEC
6-K Foreign company current report December 15, 2025 View on SEC

Annual Reports

20-F March 19, 2026
  • VYVGART's exceptional global sales of $1.20 billion in 2023, driving 158% overall sales growth to $1.23 billion.
  • Successful expansion of VYVGART's market with U.S. FDA approval of subcutaneous VYVGART Hytrulo and approval for CIDP in June 2024.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.